Cingulate expects CTx-1301 resubmission Dec. 2026–Jan. 2027
The FDA is expected to classify a resubmission as Class 1 or Class 2, with review goals of two or six months, respectively.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Cingulate Inc. expects to resubmit the CTx-1301 New Drug Application between December 2026 and January 2027. The FDA’s June 1, 2026, Complete Response Letter requested additional chemistry, manufacturing and controls information and raised no concerns regarding clinical safety or efficacy.
Cingulate and its contract drug manufacturing organization have substantially completed the requested manufacturing work and are finalizing supporting data and documentation. Subject to FDA approval, the company says commercial launch could begin in the third quarter of 2027.
Filing Explained
The FDA’s review class remains undecided until resubmission: Class 1 and Class 2 carry two- and six-month review goals, respectively, so the filing adds a review-timing fork, not an approval.
8-K Event Classification
3 items: 7.01, 8.01, 9.01
3 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
PDUFA target action date: May 31, 2026
CRL received: June 1, 2026
Expected NDA resubmission: Between December 2026 and January 2027
+5 more
8 metrics
PDUFA target action date
May 31, 2026
The FDA assigned this date after accepting the CTx-1301 NDA for review.
CRL received
June 1, 2026
Date the FDA issued the CTx-1301 Complete Response Letter.
Expected NDA resubmission
Between December 2026 and January 2027
Cingulate's current expectation.
Class 1 review goal
2 months
FDA review goal for a Class 1 resubmission.
Class 2 review goal
6 months
FDA review goal for a Class 2 resubmission.
Potential commercial launch
Third quarter of 2027
Could commence subject to FDA approval.
Estimated U.S. ADHD market
Approximately 100 million annual prescriptions
Market estimate stated in the press release.
U.S. patients diagnosed with ADHD
Over 20 million patients
Press release estimate.
Key Terms
Complete Response Letter, New Drug Application, chemistry, manufacturing and controls, Prescription Drug User Fee Act, +2 more
6 terms
Complete Response Letter regulatory
"FDA's Complete Response Letter (CRL)"
A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.
New Drug Application regulatory
"New Drug Application (NDA)"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
chemistry, manufacturing and controls technical
"additional chemistry, manufacturing and controls (CMC) information"
Chemistry, manufacturing and controls (CMC) is the package of technical information that explains how a drug or biologic is made, tested and kept consistent, submitted to regulators to demonstrate the product’s safety, purity and reliable production. Investors care because robust CMC lowers the risk of manufacturing delays, regulatory rejection or costly recalls — think of it as the product’s recipe and kitchen controls that determine whether a medicine can be scaled, sold and generate revenue.
Prescription Drug User Fee Act regulatory
"Prescription Drug User Fee Act (PDUFA) targeted action date"
A federal program that lets drug makers pay fees to the U.S. regulator to fund and speed up the review of new medicines and label changes. Investors care because it affects how quickly a drug can move from testing to market and how predictable approval timelines and regulatory interactions are — like buying a faster lane at a busy checkpoint that can reduce uncertainty about a product’s commercial timing.
505(b)(2) pathway regulatory
"under the FDA's 505(b)(2) pathway"
A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.
Erosion Barrier Layer technical
"proprietary Erosion Barrier Layer (EBL)"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does CING expect to resubmit CTx-1301?
Cingulate currently expects to submit the CTx-1301 NDA resubmission between December 2026 and January 2027. The company says it is finalizing supporting data and documentation after substantially completing the manufacturing work addressing the FDA’s requests.
What did the FDA request in CING's CTx-1301 Complete Response Letter?
The FDA requested additional chemistry, manufacturing and controls (CMC) information. The company said the letter did not raise concerns regarding CTx-1301’s clinical safety or efficacy.
How long could FDA review CING's CTx-1301 resubmission?
The FDA is expected to classify a resubmission as Class 1 or Class 2, with review goals of two months and six months, respectively. The classification would follow receipt of a resubmission.
When could CING launch CTx-1301?
Cingulate says commercial launch could commence in the third quarter of 2027, subject to FDA approval. The company cautions that there is no assurance about the timing or occurrence of a launch.
AI-generated analysis. How Rhea-AI works. Not financial advice.
